Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | PI4KA | P42356 | 1/20 | 0.31 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.31 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.31 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2204873 | 0.64 | CYP11B1 (0.44) | CYP3A4HTTEGFRMEN1ALOX15 | |
| SCHEMBL562523 | 0.64 | NOTUM (0.39) | CYP3A4NOTUMKDM4EHPGDHTT | |
| SCHEMBL1377544 | 0.62 | KDM4E (0.35) | CYP3A4NOTUMKDM4EHPGDGAA | |
| SCHEMBL44283 | 0.62 | CYP3A4 (0.32) | CYP3A4KDM4EHPGDGAAMEN1 | |
| SCHEMBL15270637 | 0.61 | ALDH1A1 (0.34) | CYP3A4KDM4EHPGDHTTGAA | |
| SCHEMBL63013 | 0.60 | CYP3A4 (0.40) | CYP3A4NOTUMKDM4EHPGDGAA | |
| SCHEMBL17186577 | 0.60 | KDM4E (0.39) | CYP3A4NOTUMKDM4EHPGDHTT | |
| SCHEMBL7986688 | 0.59 | CYP3A4 (0.34) | CYP3A4NOTUMKDM4EHPGDGAA | |
| SCHEMBL324455 | 0.59 | NOTUM (0.39) | CYP3A4NOTUMKDM4EHPGDGAA | |
| SCHEMBL29260942 | 0.58 | ALDH1A1 (0.39) | CYP3A4NOTUMKDM4EHPGDHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303569-A1 | HETEROCYCLIC COMPOUNDS AS THERAPEUTIC AGENTS | ARISAN THERAPEUTICS INC. (US) | 2023-09-28 | — | — | US | claimed |
| US-11352328-B2 | Heterocyclic compounds for the treatment of arenavirus | ARISAN THERAPEUTICS INC. (US) | 2022-06-07 | — | — | US | claimed |
| WO-2022108849-A1 | HETEROCYCLIC COMPOUNDS AS THERAPEUTIC AGENTS | ARISAN THERAPEUTICS INC. (US) | 2022-05-27 | — | — | WO | claimed |
| US-20190308938-A1 | Heterocyclic Compounds for the Treatment of Arenavirus | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-10-10 | — | — | US | claimed |
| US-5185027-A | Salicylaldehyde derivatives and salicyclic acid derivatives and their sulfur analogs, and their use as herbicides and bioregulators | BASF AKTIENGESELLSCHAFT (DE) | 1993-02-09 | — | — | US | claimed |
| US-5085686-A | Plant growth regulator | BASF AKTIENGESELLSCHAFT (DE) | 1992-02-04 | — | — | US | claimed |
| US-20230303569-A1 | HETEROCYCLIC COMPOUNDS AS THERAPEUTIC AGENTS | ARISAN THERAPEUTICS INC. (US) | 2023-09-28 | — | — | US | disclosed |
| US-11352328-B2 | Heterocyclic compounds for the treatment of arenavirus | ARISAN THERAPEUTICS INC. (US) | 2022-06-07 | — | — | US | disclosed |
| WO-2022108849-A1 | HETEROCYCLIC COMPOUNDS AS THERAPEUTIC AGENTS | ARISAN THERAPEUTICS INC. (US) | 2022-05-27 | — | — | WO | disclosed |
| US-20190308938-A1 | Heterocyclic Compounds for the Treatment of Arenavirus | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-10-10 | — | — | US | disclosed |
| CN-104011022-A | 4-aminocarbazole compound and use of same | TOSOH CORP | 2014-08-27 | — | — | CN | disclosed |
| CN-103391941-A | Imidazo [5,1-f ] [1,2,4] triazines for the treatment of neurological disorders | PFIZER | 2013-11-13 | — | — | CN | disclosed |
| US-7427616-B2 | Condensed pyridines and pyrimidines with tie2 (TEK) activity | ASTRAZENECA AB (SE) | 2008-09-23 | — | — | US | disclosed |
| US-5308828-A | Herbicides | BASF AKTIENGESELLSCHAFT (DE) | 1994-05-03 | — | — | US | disclosed |
| US-5246914-A | Fungicides and plant growth regulators | BASF AKTIENGESELLSCHAFT (DE) | 1993-09-21 | — | — | US | disclosed |
| EP-0527378-A1 | Salicyl(thio)ethers derivatives, process and intermediates for their preparation | BASF Aktiengesellschaft (DE) | 1993-02-17 | — | — | EP | disclosed |
| US-5185027-A | Salicylaldehyde derivatives and salicyclic acid derivatives and their sulfur analogs, and their use as herbicides and bioregulators | BASF AKTIENGESELLSCHAFT (DE) | 1993-02-09 | — | — | US | disclosed |
| EP-0490224-A2 | Derivatives of salicylic aldehyde and salicylic acid, sulfphuranalogs thereof, process and intermediates for their preparation | BASF Aktiengesellschaft (DE) | 1992-06-17 | — | — | EP | disclosed |
| US-5085686-A | Plant growth regulator | BASF AKTIENGESELLSCHAFT (DE) | 1992-02-04 | — | — | US | disclosed |
| EP-0402751-A1 | Derivatives of salicylic aldehyde and salicylic acid and sulphur analoges thereof, methodes for preparing them and their use as herbicides and bioregulators | BASF Aktiengesellschaft (DE) | 1990-12-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303569-A1 | HETEROCYCLIC COMPOUNDS AS THERAPEUTIC AGENTS | C3AR1, C9, C1R | CYP3A4 344/4885NOTUM 2636/4885KDM4E 3105/4885 |
| US-11352328-B2 | Heterocyclic compounds for the treatment of arenavirus | C9, C1R, C1S | CYP3A4 1866/4885NOTUM 2068/4885KDM4E 838/4885 |
| US-20190308938-A1 | Heterocyclic Compounds for the Treatment of Arenavirus | C9, C1R, C1S | CYP3A4 1866/4885NOTUM 2068/4885KDM4E 838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.